Why Is Celularity Stock Gaining Thursday?
Celularity (CELU) stock surged 131% following a $300M U.S. manufacturing collaboration with MuseCell Innovations in New Jersey.
Stocks · News reference
Celularity shares are trading higher after the company announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier: Celularity And MuseCell Innovations Expand U.S. Manufacturing Collaboration, With Potential For $300M+ In Purchases Over Five Years
Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa
Celularity To Begin U.S. Production Of MuseCell Innovations' Dezawa MuseCells At Its New Jersey Facility
The initial program is designed to establish manufacturing capability for MCI-authenticated DMC preparations. Under the MCI platform, a preparation is authenticated as a DMC product through perinatal, bone marrow or